Connect your AI

CG Oncology CGON Operating Cash Flow

Operating Cash Flow at other companies

PfizerPFE

$2.62B+12.0%

Johnson & JohnsonJNJ

$2.51B-39.8%

Gilead SciencesGILD

$2.54B+44.8%

ImmunityBio, Inc.IBRX

-$75.36M+12.3%

Cogent Biosciences, Inc.COGT

-$86.88M-30.6%

Tango TherapeuticsTNGX

-$44.36M-6.4%

Other financials

Income statement

Revenue$1.1M+1,983%

Operating income-$66.4M-57.3%

Net income-$60.2M-74.7%

EPS (diluted)-$0.71-57.8%

Balance sheet

Cash & equivalents$33.7M-18.7%

Total debt$7.6M+631%

Total equity$1.1B+54.9%

Total assets$1.1B+55.9%

Cash flow

CapEx$304.0K+1,800%

Free cash flow-$57.2M-95.4%

Valuation

Market cap$5.39B+206%

Profitability

Operating margin-4,239%-1,872pp

Net margin-3,682.6%-1,601pp

FCF margin-3,163.8%-1,351pp

Returns & leverage

Return on equity-20.8%+7.1pp

Debt / equity0×0.0×

Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CG Oncology's operating cash flow?: CG Oncology (CGON) reported operating cash flow of -$56.94M in Q1 2026.
How has CG Oncology's operating cash flow changed year-over-year?: CG Oncology's operating cash flow decreased by 94.5% year-over-year, from -$29.28M to -$56.94M.
What is the long-term trend for CG Oncology's operating cash flow?: Over 2 years (2023 to 2025), CG Oncology's operating cash flow has grown at a 70.2% compound annual growth rate (CAGR), from -$45.68M to -$132.35M.
What does operating cash flow mean?: Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.